The effects of various beta-adrenoceptor agents on radioiodine release from the thyroid were studied in mice pretreated with 125I and thyroxine. The non-selective beta-adrenoceptor agonist isopropylnoradrenaline and the selective beta 2-adrenoceptor agonist terbutaline both, and with the same efficacy, enhanced radioiodine release, whereas the selective beta 1-adrenoceptor agonist prenalterol had no such effect. The non-selective beta-adrenoceptor antagonist L-propranolol and the selective beta 2-adrenoceptor antagonist ICI 118,551 both abolished the radioiodine release induced by isopropylnoradrenaline or by terbutaline. The selective beta 1-adrenoceptor antagonist metoprolol inhibited the radioiodine response to isopropylnoradrenaline, but not that to terbutaline. Neither of the beta-adrenoceptor antagonists influenced the radioiodine release induced by TSH. It is concluded that the beta-adrenoceptors involved in the regulation of thyroid hormone secretion are mainly of the beta 2-subtype, and, further, that beta-adrenoceptor agonists and TSH exert their thyroid hormone secretory effects through different mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0014-2999(83)90590-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Trials in Cancer Theranostics with Potential Near-Term Impact on Clinical Practice.
Br J Radiol
January 2025
Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Theranostics has its roots with the first radioiodine therapy for thyroid diseases in about 80 years ago. More recently the field has experienced a remarkable renascence with the regulatory approval of paired imaging and radiopharmaceutical therapy agents in gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancer that are now employed in routine clinical practice. The momentum is strong for identification and testing of new theranostic agents for use in various cancers and finding new clinical incications of the available agents.
View Article and Find Full Text PDFThe Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge.
Int J Mol Sci
December 2024
Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania.
Starting from the metabolic profile of type 2 diabetes mellitus (T2DM), we hypothesized that the mechanisms of ¹³¹I-induced cardiotoxicity differ between patients diagnosed with differentiated thyroid cancer (DTC) with/without T2DM, with metformin potentially acting as a cardioprotective agent by mitigating inflammation in patients with T2DM. To address this hypothesis, we quantified, using ELISA, the serum concentration of several key biomarkers that reflect cardiac injury (NT-proBNP, NT-proANP, ST2/IL-33R, and cTn I) in 74 female patients with DTC/-T2DM and 25 with DTC/+T2DM treated with metformin. All patients received a cumulative oral dose of I exceeding 150 mCi (5.
View Article and Find Full Text PDFA study on the performance of enhancing environmental protection from molecular iodine using granular impregnated activated carbon.
Environ Sci Pollut Res Int
December 2024
Hazardous Air Pollutants Laboratory, Pakistan Institute of Engineering & Applied Sciences, Islamabad, Pakistan.
Environmentally hazardous radioactive isotopes of iodine may be released from a nuclear power plant as a by-product of uranium fission. The efficient and safe capture of volatile radioiodine is of great significance in the history of nuclear power plants. Due to its high volatility and carcinogenic characteristics, elimination of iodine gas (I) from air is the need of the hour from an environmental and health point of view.
View Article and Find Full Text PDFChemical form of volatilized iodine obtained from orchard grass (Dactylis glomerata L.).
Radiat Prot Dosimetry
November 2024
Department of Radioecology, Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Kamikita, Aomori, 039-3212, Japan.
Japan's first commercial nuclear fuel reprocessing plant is expected to release radioiodine into the atmosphere, and orchard grass plants grown in the vicinity of this plant may absorb this radioiodine. In this study, we investigated the mechanism underlying the absorption and volatilization of iodine in the leaves of orchard grass. Our findings suggest that iodine can be transferred from the leaves of this grass to the atmosphere via two routes: direct volatilization and absorption followed by volatilization.
View Article and Find Full Text PDFReview of iodine behavior from nuclear fuel dissolution to environmental release.
RSC Adv
November 2024
Pacific Northwest National Laboratory Richland WA 99354 USA
During nuclear fuel reprocessing, radioiodine, can be released. The speciation of iodine drives its volatility, and partitioning processes are highly variable because they depend on facility operating conditions. Starting from iodine behavior in the fuel and progressing to its behavior in the environment, this review article describes the current understanding of iodine partitioning during aqueous fuel reprocessing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!